A pathogenic mechanism in Huntington"s disease involves small CAG-repeated RNAs with neurotoxic activity

dc.contributor.author
Bañez-Coronel, Mónica
dc.contributor.author
Porta, Sílvia
dc.contributor.author
Kagerbauer, Birgit
dc.contributor.author
Mateu Huertas, Elisabet
dc.contributor.author
Pantano, Lorena
dc.contributor.author
Ferrer, Isidro (Ferrer Abizanda)
dc.contributor.author
Guzmán, Manuel
dc.contributor.author
Estivill, Xavier, 1955-
dc.contributor.author
Martí Puig, Eulàlia
dc.date.issued
2014-01-23T11:59:36Z
dc.date.issued
2014-01-23T11:59:36Z
dc.date.issued
2012-02-23
dc.date.issued
2014-01-23T11:59:36Z
dc.identifier
1553-7390
dc.identifier
https://hdl.handle.net/2445/49112
dc.identifier
631804
dc.identifier
22383888
dc.description.abstract
Huntington's disease (HD) is an autosomal dominantly inherited disorder caused by the expansion of CAG repeats in the Huntingtin (HTT) gene. The abnormally extended polyglutamine in the HTT protein encoded by the CAG repeats has toxic effects. Here, we provide evidence to support that the mutant HTT CAG repeats interfere with cell viability at the RNA level. In human neuronal cells, expanded HTT exon-1 mRNA with CAG repeat lengths above the threshold for complete penetrance (40 or greater) induced cell death and increased levels of small CAG-repeated RNAs (sCAGs), of ≈21 nucleotides in a Dicer-dependent manner. The severity of the toxic effect of HTT mRNA and sCAG generation correlated with CAG expansion length. Small RNAs obtained from cells expressing mutant HTT and from HD human brains significantly decreased neuronal viability, in an Ago2-dependent mechanism. In both cases, the use of anti-miRs specific for sCAGs efficiently blocked the toxic effect, supporting a key role of sCAGs in HTT-mediated toxicity. Luciferase-reporter assays showed that expanded HTT silences the expression of CTG-containing genes that are down-regulated in HD. These results suggest a possible link between HD and sCAG expression with an aberrant activation of the siRNA/miRNA gene silencing machinery, which may trigger a detrimental response. The identification of the specific cellular processes affected by sCAGs may provide insights into the pathogenic mechanisms underlying HD, offering opportunities to develop new therapeutic approaches
dc.format
15 p.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
Public Library of Science (PLoS)
dc.relation
Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pgen.1002481
dc.relation
PLoS Genetics, 2012, vol. 8, num. 2, e1002481
dc.relation
http://dx.doi.org/10.1371/journal.pgen.1002481
dc.rights
cc-by (c) Bañez-Coronel, M. et al., 2012
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Corea de Huntington
dc.subject
Pèptids
dc.subject
Teixit nerviós
dc.subject
Neurotoxines
dc.subject
Huntington's chorea
dc.subject
Peptides
dc.subject
Nerve tissue
dc.subject
Neurotoxins
dc.title
A pathogenic mechanism in Huntington"s disease involves small CAG-repeated RNAs with neurotoxic activity
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)